Glenmark Pharmaceuticals Ltd

Announcement under Regulation 30 (LODR)-Press Release / Media Release

03:35 PM, 16th Dec 2025

Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib an MHRA and NMPA approved Third - Generation EGFR-TKI from Hansoh Pharma